Literature DB >> 26719231

A new standard for malignant pleural mesothelioma.

Marjorie G Zauderer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719231      PMCID: PMC5464401          DOI: 10.1016/S0140-6736(15)01311-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.

Authors:  L Strizzi; A Catalano; G Vianale; S Orecchia; A Casalini; G Tassi; R Puntoni; L Mutti; A Procopio
Journal:  J Pathol       Date:  2001-04       Impact factor: 7.996

2.  Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

Authors:  Matthew D Hellmann; Mark G Kris; Charles M Rudin
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

Review 3.  Searching for targets for the systemic therapy of mesothelioma.

Authors:  R A Stahel; W Weder; E Felley-Bosco; U Petrausch; A Curioni-Fontecedro; I Schmitt-Opitz; S Peters
Journal:  Ann Oncol       Date:  2015-02-26       Impact factor: 32.976

4.  Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Authors:  Hedy L Kindler; Gregory Friberg; Deepti A Singh; Gershon Locker; Sreenivasa Nattam; Mark Kozloff; David A Taber; Theodore Karrison; Abraham Dachman; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

5.  New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Authors:  Marc Ladanyi; Marjorie G Zauderer; Lee M Krug; Tatsuo Ito; Robert McMillan; Matthew Bott; Filippo Giancotti
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

6.  A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Authors:  Sarita Dubey; Pasi A Jänne; Lee Krug; Herbert Pang; Xiaofei Wang; Robin Heinze; Colleen Watt; Jeff Crawford; Robert Kratzke; Everett Vokes; Hedy Lee Kindler
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

7.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Authors:  Thierry Jahan; Lin Gu; Robert Kratzke; Arkadiusz Dudek; Gregory A Otterson; Xiaofei Wang; Mark Green; Everett E Vokes; Hedy Lee Kindler
Journal:  Lung Cancer       Date:  2011-12-22       Impact factor: 5.705

8.  Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.

Authors:  Wieneke A Buikhuisen; Jacobus A Burgers; Andrew D Vincent; Catharina M Korse; Rob J van Klaveren; Franz M N H Schramel; Nick Pavlakis; Anna K Nowak; Frank L J Custers; J Hugo Schouwink; Steven J M Gans; Harry J M Groen; Wim F M Strankinga; Paul Baas
Journal:  Lancet Oncol       Date:  2013-04-12       Impact factor: 41.316

Review 9.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

10.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

Authors:  Y Ohta; V Shridhar; R K Bright; G P Kalemkerian; W Du; M Carbone; Y Watanabe; H I Pass
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  1 in total

1.  The necessity of a more aggressive initial surgical treatment in patients with mesothelioma of the testicular tunica vaginalis.

Authors:  Clement Brun; Sophie Giusiano; Khady Thiam; Julien Guinde; Marios Froudarakis; Philippe Astoul
Journal:  Ann Med Surg (Lond)       Date:  2019-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.